Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Is Reinvesting In Diabetes, Injecting New Life Into Humalog Franchise

Executive Summary

Lilly is striving to reenergize its Humalog franchise in 2006 through a pending line extension and an expansion of its insulin production capacity, as the company seeks to rebuild its traditional strength in the diabetes category
Advertisement

Related Content

Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead
Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead
Inhaled Insulin Manufacturers Find Size Matters After Exubera Cmte. Review
Inhaled Insulin Manufacturers Find Size Matters After Exubera Cmte. Review
Amylin/Lilly Byetta Clears FDA As Adjunct Diabetes Therapy; Launch Is June
Advertisement
UsernamePublicRestriction

Register

PS046707

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel